Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News
Price
Movement
52 Week Range
1 Year Return
() Chart and Price Data
Fundamental Company Figures
Data provided by Morningstar.Clinuvel Pharmaceuticals Limited (ASX: CUV) Latest News
Clinuvel (ASX:CUV) share price drops on strategic update
Marc Sidarous | April 12, 2021 2:50pm
Clinuvel (ASX:CUV) share price falls despite positive update
Aaron Teboneras | March 24, 2021 11:28am
These were the best performers on the ASX 200 last week
James Mickleboro | March 20, 2021 7:30am
These were the best performing ASX 200 shares last week
James Mickleboro | March 13, 2021 9:05am
Clinuvel (ASX:CUV) share price down despite recording 10th consecutive net profit
Nikhil Gangaram | February 24, 2021 2:43pm
Clinuvel (ASX:CUV) share price pinches down after Israeli breakthrough
Gretchen Kennedy | February 11, 2021 5:57pm
Dividend Payment History
Data provided by Morningstar.| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 03 Sep 2020 | $0.0250 | 0.00% | Final | 18 Sep 2020 |
| 04 Sep 2019 | $0.0250 | 0.00% | Final | 19 Sep 2019 |
| 21 Sep 2018 | $0.0200 | 0.00% | Final | 08 Oct 2018 |
Yearly Dividend Payment Chart
Data provided by Morningstar.Recent Stock Announcements
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About Clinuvel Pharmaceuticals Ltd (ASX: CUV)
Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company that develops drugs for the treatment of a range of skin disorders. The company’s flagship product is Scenesse, a drug designed for the treatment of erythropoietic protoporphyria (EPP). EPP is a rare metabolic disorder which causes burns after brief exposure to visible light, especially sunlight. It is estimated that there are 5,000 to 10,000 EPP patients worldwide.
Clinuvel is also seeking to progress the use of Scenesse for the treatment of vitiligo, a skin disorder characterised by the appearance of white to off-white skin patches due to the loss of melanin production.
The company’s history dates back to 1987 when university researchers devised an idea of synthesising human hormones to protect the skin. Clinuvel shares have been listed on the ASX since 2001 and as a biopharmaceutical company, the Clinuvel share price can often be particularly volatile, bouncing around in response to announcements such as clinical trials and new launches.
Share Price History
Data provided by Morningstar.| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 12 Apr 2021 | $29.45 | $-0.67 | -2.22% | 120,551 | $30.12 | $30.27 | $29.23 |
| 09 Apr 2021 | $30.12 | $0.33 | 1.11% | 92,793 | $29.81 | $30.61 | $29.79 |
| 08 Apr 2021 | $29.79 | $1.17 | 4.09% | 112,813 | $28.64 | $30.00 | $28.32 |
| 07 Apr 2021 | $28.62 | $0.44 | 1.56% | 82,022 | $28.18 | $28.93 | $27.82 |
| 06 Apr 2021 | $28.18 | $0.54 | 1.95% | 56,203 | $28.30 | $28.82 | $27.74 |
| 01 Apr 2021 | $27.64 | $0.57 | 2.11% | 50,968 | $26.90 | $27.75 | $26.50 |
| 31 Mar 2021 | $27.07 | $0.07 | 0.26% | 120,111 | $26.79 | $27.48 | $26.39 |
| 30 Mar 2021 | $27.00 | $-0.68 | -2.46% | 85,286 | $27.51 | $27.96 | $26.97 |
| 29 Mar 2021 | $27.68 | $-0.59 | -2.09% | 41,365 | $28.42 | $28.50 | $27.68 |
| 26 Mar 2021 | $28.27 | $-0.21 | -0.74% | 109,176 | $28.40 | $28.96 | $28.02 |
| 25 Mar 2021 | $28.48 | $0.57 | 2.04% | 92,577 | $27.95 | $28.78 | $27.51 |
| 24 Mar 2021 | $27.91 | $-0.73 | -2.55% | 104,903 | $28.00 | $28.38 | $27.63 |
| 23 Mar 2021 | $28.64 | $0.70 | 2.51% | 112,877 | $28.02 | $28.80 | $27.98 |
| 22 Mar 2021 | $27.94 | $-0.35 | -1.24% | 92,359 | $28.04 | $28.78 | $27.68 |
| 19 Mar 2021 | $28.29 | $0.97 | 3.55% | 188,822 | $27.30 | $28.43 | $27.07 |
| 18 Mar 2021 | $27.32 | $-0.14 | -0.51% | 121,381 | $27.02 | $27.70 | $26.99 |
| 17 Mar 2021 | $27.46 | $0.82 | 3.08% | 142,204 | $26.54 | $27.69 | $26.24 |
| 16 Mar 2021 | $26.64 | $0.24 | 0.91% | 119,378 | $26.60 | $27.00 | $26.43 |
| 15 Mar 2021 | $26.40 | $1.10 | 4.35% | 140,256 | $25.55 | $26.75 | $25.05 |
Director Transactions
Data provided by Morningstar.Directors & Management
Data provided by Morningstar.Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 14,860,373 | 30.08% |
| HSBC Custody Nominees (Australia) Limited | 9,877,178 | 19.99% |
| Acn 108 768 896 Pty Ltd | 4,324,693 | 8.75% |
| Ender 1 Llc | 2,590,824 | 5.24% |
| Citicorp Nominees Pty Limited | 1,540,396 | 3.12% |
| Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retail Client) | 1,002,756 | 2.03% |
| National Nominees Limited | 636,062 | 1.29% |
| M Badcock And P Chu Superannuation Fund Pty Ltd | 628,447 | 1.27% |
| Dr Mark Edwin Badcock | 567,890 | 1.15% |
| Bnp Paribas Noms Pty Ltd (Drp) | 557,672 | 1.13% |
| National Nominees Limited (Db A/C) | 481,667 | 0.97% |
| Merrill Lynch (Australia) Nominees Pty Limited | 323,059 | 0.65% |
| BNP Paribas Noms (NZ) Ltd (DRP) | 261,411 | 0.53% |
| Mr David William Trevorrow | 222,222 | 0.45% |
| Bnp Paribas Nominees Pty Ltd (Agency Lending Drp A/C | 220,669 | 0.45% |
| Bnp Paribas Nominees Pty Ltd (Lgt Bank Ag Drp) | 213,770 | 0.43% |
| Vulcancrest Pty Ltd (The Vulancrets A/C) | 200,000 | 0.40% |
| Ms Nicoletta Muner | 187,625 | 0.38% |
| Hsbc Custody Nominees (Australia) Limited AA/C 2 | 187,000 | 0.38% |
| Mr David John Lewis | 183,165 | 0.37% |
FAQ
Will Clinuvel Pharmaceuticals pay a dividend in 2020?
Clinuvel Pharmaceuticals listed on the ASX in 2001 and only recently declared a profit for the first time in FY2017. Since then, the company went on to achieve increased profits across both FY2018 and FY2019. It also distributed final dividends of 2 cents and 2.5 cents per share for FY2018 and FY2019 respectively. As at 17 June 2020, Clinuvel has made no announcements regarding the status of its FY2020 dividend payment.
Does Clinuvel Pharmaceuticals offer a DRP?
Having only started paying dividends over the last couple of years, Clinuvel Pharmaceuticals does not currently offer a dividend reinvestment plan.